Archana Gulia*
In case of global pandemic corona virus disease 2019, clinical trials and research are assessing efficacy and safety for clinical patients for treating covid-19 as, it is evolving at unprecedented rate, by tracking clinical trials done and avoiding duplication efforts and phase2 clinical trials evaluate new therapeutics and by including investigational therapeutic effort on synthetic monoclonal antibodies (mAbs) for treating disease. Trials designed to elaborate test multiple different kind of monoclonal antibody treatment.